Soligenix Shares Are Trading Lower After the Company Announced Clinical Results From a Comparative Study Evaluating HyBryte Against Valchlor in the Treatment of Cutaneous T-cell Lymphoma. The Stock Initially Traded Higher, but It Has Since Reversed.
Soligenix Shares Are Trading Lower After the Company Announced Clinical Results From a Comparative Study Evaluating HyBryte Against Valchlor in the Treatment of Cutaneous T-cell Lymphoma. The Stock Initially Traded Higher, but It Has Since Reversed.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.